Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AQST stock, giving a Buy rating on September 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz’s rating is based on several key factors that highlight the potential of Aquestive Therapeutics. The recent announcement that the FDA does not require an advisory committee meeting for Anaphylm is a significant de-risking event, reducing regulatory uncertainty for this innovative sublingual epinephrine product. This decision is seen as a positive development that contrasts with previous expectations and has already led to a notable increase in the company’s stock price.
Additionally, Ruiz points out that Aquestive’s management has effectively positioned the company for a potential commercial launch through strategic financing activities. This, combined with the robust clinical data supporting Anaphylm, strengthens the company’s standing in the competitive Type 1 allergy market. Ruiz believes that the market can support multiple no-needle epinephrine solutions, and Aquestive’s differentiated offering positions it well for future success.
According to TipRanks, Ruiz is an analyst with an average return of -0.9% and a 47.83% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as United Therapeutics, Aquestive Therapeutics, and Lantheus.
In another report released on September 6, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $10.00 price target.